GPP
IMVT icon

Great Point Partners’s Immunovant IMVT Stock Holding History

Great Point Partners’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-545,625
Closed -$13.6M – 49
2026
Q1 		$13.6M Sell
545,625
-204,375
-27% -$5.29M 3.11% 12
2025
Q4 		$19.1M Buy
750,000
+250,000
+50% +$5.57M 6.18% 6
2025
Q3 		$8.06M Buy
500,000
+237,824
+91% +$3.85M 3.32% 11
2025
Q2 		$4.19M Sell
262,176
-112,824
-30% -$1.71M 2.73% 14
2025
Q1 		$6.41M Buy
+375,000
New +$7.84M 3.39% 13

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Great Point Partners's IMVT Position: Q2 2026 in Review

Great Point Partners sold out of Immunovant (IMVT) in Q2 2026, closing a stake of 545,625 shares — an estimated $13.6M sold.

Great Point Partners first reported a position in IMVT in Q1 2025 and held it in 5 quarters. The position peaked at $19.1M in Q4 2025. 226 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • Great Point Partners reported no remaining Immunovant position as of Q2 2026 after selling out during the quarter.
  • Great Point Partners sold 545,625 Immunovant shares in Q2 2026, an estimated $13.6M.
  • Great Point Partners first reported a position in Immunovant in Q1 2025 and held it in 5 quarters.
  • Great Point Partners's Immunovant position peaked at $19.1M in Q4 2025.
  • 226 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Great Point Partners's 13F filing for Q2 2026, filed 14 Aug 2026.